ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo

Get full text

Publisher Correction: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo

Get full text

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial by Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac

Get full text

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context by Maxwell R. Lloyd, Rosario Chica-Parrado, Caroline M. Weipert, Todd C. Knepper, Emily L. Podany, Fabiana Napolitano, Dan Ye, Chang-Ching Lin, Yasuaki Uemoto, Jiemin Liao, Claire Wegrzyn, Christine M. Walko, Lianne Y. Ryan, Jennifer C. Keenan, Arielle J. Medford, Shiyuan A. Liu, Gerburg M. Wulf, Katherine K. Clifton, Cynthia X. Ma, Hyo S. Han, Nicole Zhang, Leif W. Ellisen, Aditya Bardia, Carlos L. Arteaga, Ariella B. Hanker, Seth A. Wander

Get full text